 SAN DIEGO, Aug. 04, 2020 GLOBE NEWSWIRE -- Kura Oncology, Inc. Nasdaq: KURA, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Tuesday, August 11, 2020 at 2:20 p.m. ET 11:20 a.m. PT. The virtual conference will be held from August 11-12, 2020. A live audio webcast of the presentation will be available in the Investors section of Kuras website at with an archived replay available for 30 days following the event.About Kura OncologyKura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Companys pipeline consists of two wholly owned, small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kuras most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial AIM-HN in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Companys pipeline is also highlighted by KO-539, a potent and selective inhibitor of the menin-KMT2AMLL protein-protein interaction currently in a Phase 12A clinical trial KOMET-001 in patients with relapsedrefractory acute myeloid leukemia. For additional information about Kura, please visit the Companys website at Pete De Spain Vice President, Investor Relations Corporate Communications 858 500-8803 Robert H. Uhl Managing Director Westwicke ICR 858 356-5932 Jason Spark Managing Director Canale Communications 619 849-6005 